Global News

Cardiome reduces work force by 85%

Monday, July 9, 2012 03:03 PM

Vancouver-based Cardiome Pharma, a research-based biopharmaceutical company, is undertaking a significant work force reduction in response to the recently announced termination of Merck's development efforts relating to the vernakalant oral program.

More... »

ERT acquires invivodata

Monday, July 9, 2012 01:38 PM

ERT, a global technology-driven provider of health outcomes services, has decided to acquire invivodata, a provider of electronic Patient Reported Outcomes (ePRO) solutions and consulting services, based in Pittsburgh, Penn.

More... »

R-Pharm licenses Merck hepatitis C drug

Friday, July 6, 2012 03:59 PM

The Russian pharmaceutical company R-Pharm—headed by the Ministry of Industry and Trade of the Russian Federation—entered into a licensing agreement with MSD (Merck) for rights to a novel investigational, hepatitis C once-daily protease inhibitor, narlaprevir. 

More... »

Roche receives FDA approval for cytomegalovirus viral load test

Friday, July 6, 2012 03:20 PM

Switzerland-based Roche has received premarket approval from the FDA for a new test to assess a patient's viral load of cytomegalovirus (CMV).

More... »

CRT and ADC Therapeutics partner on antibody drug conjugates

Friday, July 6, 2012 03:02 PM

Cancer Research Technology (CRT), the commercial arm of Cancer Research U.K., and Switzerland-based ADC Therapeutics have signed agreements to develop cancer treatments called antibody drug conjugates (ADCs) using CRT antibodies and peptides and ADCT's “warhead” and linker chemistries.

More... »

Pfizer grants ChemRar Group exclusive license to DPP-IVi T2D candidate

Friday, July 6, 2012 02:47 PM

Pfizer has granted  SatRx , a company belonging to Russian pharmaceutical investment and R&D group  ChemRar Hi-Tech Centre , exclusive development and marketing rights to for its DPP(1)-IVi compound, PF-00734200.

More... »

Sucampo Pharmaceuticals announces arbitration decision

Friday, July 6, 2012 02:32 PM

Sucampo Pharmaceuticals of Bethesda, Md.,has received a final binding decision on its claims in the dispute with its partner, Takeda Pharmaceutical: the International Court of Arbitration, International Chamber of Commerce (ICC) did not agree with Sucampo's claims and did not award any attorneys' fees or costs.

More... »

Amgen completes acquisition of KAI Pharmaceuticals

Friday, July 6, 2012 02:13 PM

Thousand Oaks, Calif.-based Amgen has completed the acquisition of KAI Pharmaceuticals, a privately held company based in South San Francisco.

More... »

CTO launched to make Ontario preferred location for global clinical trials

Friday, July 6, 2012 12:04 PM

Clinical Trials Ontario (CTO), a province-wide entity to make Ontario the preferred location for global clinical trials activity while maintaining the highest ethical standards, has officially launched.

More... »

Shionogi launches new European headquarters in London

Friday, July 6, 2012 11:47 AM

Japan-based pharmaceutical company Shionogi & Co. has launched its new European headquarters in London, to be called Shionogi Limited.

More... »